INDIANAPOLIS, Dec. 3, 2021 /PRNewswire/ -- The U.S.Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to